The findings, published by The BMJ Aug. 19, 2020, show that targeted radiotherapy at the time of surgery to remove the tumor is associated with around an 80% chance of avoiding a full course of conventional radiotherapy, and had fewer side effects and no difference in survival or likelihood of the cancer returning.
The study involved 2,298 women, aged 45 or older, who were eligible for breast conservation surgery (lumpectomy) at 32 centers in 10 countries in the UK, Europe, Australia, USA and Canada. About half of them (1,140 women) were randomly assigned to receive targeted intraoperative radiotherapy (TARGIT-IORT) and 1,158 received conventional external beam radiotherapy (EBRT) over several weeks post surgery.
After five years of following the women, the local recurrence risk was 2.11% for TARGIT-IORT compared with 0.95% for EBRT. This difference of 1.16% is not considered clinically significant.
In the first five years after surgery, there were 13 additional local recurrences (24 out of 1,140 vs 11 out of 1,158) but 14 fewer deaths (42 out of 1,140) in the TARGIT-IORT group vs 56 out of 1,158 who received EBRT.
Sources: The BMJ 2020;370:m2836 and BMJ press release
After five years of following the women, the local recurrence risk was 2.11% for TARGIT-IORT compared with 0.95% for EBRT. This difference of 1.16% is not considered clinically significant.
In the first five years after surgery, there were 13 additional local recurrences (24 out of 1,140 vs 11 out of 1,158) but 14 fewer deaths (42 out of 1,140) in the TARGIT-IORT group vs 56 out of 1,158 who received EBRT.
Sources: The BMJ 2020;370:m2836 and BMJ press release
No comments:
Post a Comment